Why Elevance Health Inc. (ELV) stock moved
Elevance Health Inc. (ELV) shares rose 2.0% to $389.96 as of July 21, 2026, a modest gain from the prior close of $382.23. BestStocks flagged the session as a major change for ELV. The move is tied to an earnings beat. Below, we break down what changed for ELV, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
Elevance Health Inc. (ELV) reported EPS of $7.45 vs. $6.21 consensus estimate for Q2 FY2026, beating expectations by 20.0%. Monitor Q3 FY2026 guidance and any updates to full-year 2026 earnings expectations in the coming earnings call or investor communications.
What it means for Elevance Health Inc. investors
For Elevance Health Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 2.0% session move. Weighing against that: Elevance Health reported Q2 2026 earnings before market open showing a sharp 30% year-over-year earnings decline to ~$6.18 per share, driven by surging medical costs and worsening medical loss ratios (Established source, uk.investing.com); New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $440.17, implying +12.9% upside from $389.96. Over the past 90 days analysts logged 2 upgrades and 0 downgrades. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 91 days out, the next report is the most likely near-term test of the move.
ELV price reaction
ELV last traded at $389.96, up $7.73 (+2.02%) from the previous close of $382.23. The session traded on 0.2× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $372.85 and $426.79, and it currently sits about 32% of the way up that band.
Bullish and bearish analyst opinions on Elevance Health Inc. (ELV)
The consensus analyst price target on Elevance Health Inc. (ELV) is $440.17, 12.9% above the recent $389.96. Over the past 90 days analysts logged 2 upgrades, 26 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ELV line up.
The bullish case
- Wall Street's consensus price target of $440.17 implies +12.9% upside from $389.96.
- The Street's most bullish target is $498.00 (+27.7%).
- 2 analyst upgrades in the past 90 days, most recently Deutsche Bank to Buy (2026-05-20).
- Material positive event.
- Positive 2.0% session move.
The bearish case
- Elevance Health reported Q2 2026 earnings before market open showing a sharp 30% year-over-year earnings decline to ~$6.18 per share, driven by surging medical costs and worsening medical loss ratios (Established source, uk.investing.com).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ELV
Frequently asked questions about ELV
Why did Elevance Health Inc. (ELV) stock move?
ELV rose 2.0% to $389.96. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did ELV stock rise?
ELV gained 2.02% ($7.73) versus the prior close of $382.23, last trading at $389.96 on 0.2× average volume.
When is Elevance Health Inc.'s next earnings date?
ELV's next earnings report is estimated for 2026-10-20 — about 91 days away.
What is the analyst price target for ELV?
The consensus analyst price target for ELV is $440.17, about 12.9% above the current $389.96. Over the past 90 days, analysts recorded 2 upgrades, 26 maintains, and 0 downgrades.
How BestStocks tracks ELV
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 11 tracked change events for ELV, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.